![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, May 26, 2017 12:59:24 PM
--
We are promoting our products through targeted advertising on the internet and through social media.
Thank you for your continued interest in Premier Biomedical.
Public Relations Team
Premier Biomedical, Inc
www.premierbiomedical.com
This communication (including any attachments) contains Premier Biomedical, Inc. privileged or confidential information intended for a specific individual and purpose, and is protected by law. It is not to be forwarded or disseminated to persons without a demonstrated "need-to-know", without authorization from Premier Biomedical, Inc. If you are not the intended recipient, you should delete this communication immediately and are hereby notified that any disclosure, copying, dissemination, or distribution of this communication, or the taking of any action based on it, is strictly prohibited. If you receive this communication in error, please notify us immediately by calling 724-633-7033. This email and it’s attachments are © 2017, Premier Biomedical, Inc. All rights reserved. Any unauthorized reproduction is illegal without written consent.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM